Skip to main content

Advertisement

SpringerLink
Log in

+Microalbuminuria in hypertension

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

A body of evidence indicates that microalbuminuria is a well-recognized marker of cardiovascular complications and increased cardiovascular risk in hypertension. However, the prognostic significance of microalbuminuria remains controversial because only the results of a few prospective studies performed in small groups of hypertensive subjects without diabetes mellitus are available. Several factors can affect the prevalence of microalbuminuria in hypertension including age, sex, race, severity of the disease, and concomitant risk factors. This accounts for the large differences in the prevalence of microalbuminuria that can be found in the literature, with prevalence rates going from a low of 4.7% to a high of 46%. The main determinant of albumin excretion rate in subjects with mild hypertension and no cardiovascular complications seems to be the hemodynamic load, whereas in subjects with more severe hypertension and associated target organ damage, the augmented urinary albumin leak is probably the consequence of glomerular damage. Inhibition of the reninangiotensin system with angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists is particularly effective at reducing the albumin excretion rate, but whether these classes of drugs are more beneficial in patients with microalbuminuria remains to be determined. There is general consensus that evaluation of microalbuminuria is useful for the assessment of overall cardiovascular risk in hypertension, since albumin excretion rate appears to be a cost-effective way to identify patients at higher risk for whom additional preventive and therapeutic measures are advisable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Redon J, Williams B: Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002, 20:353–355. This review focuses on the threshold value for microalbuminuria in hypertension. It reports on the results of several studies in which the urinary albumin threshold required to define increased risk in people with hypertension was far below the threshold used for the current definition of microalbuminuria. According to the authors, the cut-off limit used to define microalbuminuria should be shifted downward in hypertension.

    Article  PubMed  CAS  Google Scholar 

  2. Rosa TT, Palatini P: Clinical value of microalbuminuria in hypertension. J Hypertens 2000, 18:645–654. A comprehensive review on microalbuminuria in hypertension that may serve as background information for the present updated review and as a helpful source of references.

    Article  PubMed  CAS  Google Scholar 

  3. Damsgaard EM, Froland A, Jorgensen OD, et al.: Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990, 300:297–300.

    Article  PubMed  CAS  Google Scholar 

  4. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, et al.: Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999, 19:1992–1997.

    PubMed  CAS  Google Scholar 

  5. Roest M, Banga JD, Janssen WM, et al.: Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001, 103:3057–3061.

    PubMed  CAS  Google Scholar 

  6. Gerstein HC, Mann JF, Yi Q, et al.: HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421–426.

    Article  PubMed  CAS  Google Scholar 

  7. American Diabetes Association and the National Kidney Foundation: Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 1994, 17:1357–1361.

    Google Scholar 

  8. Terpstra WF, May JF, Smit AJ, et al.: Microalbuminuria is related to marked end organ damage in previously untreated, elderly hypertensive patients. Blood Press 2002, 11:84–90.

    Article  PubMed  CAS  Google Scholar 

  9. Hillege HL, Janssen WM, Bak AA, et al., for the Prevend Study Group: Microalbuminuria is common, also in a nondiabetic, nonhypertensive population,and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001, 249:519–526.

    Article  PubMed  CAS  Google Scholar 

  10. Dell’Omo G, Penno G, Giorgi D, et al.: Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am J Kidney Dis 2002, 40:1–8.

    Article  PubMed  Google Scholar 

  11. Pedrinelli R, Dell’Omo G, Di Bello V, et al.: Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 2002, 16:79–89. This paper reviews the existing epidemiologic and clinical evidence about the relationships of nondiabetic microalbuminuria with cardiovascular risk factors that include blood pressure, cardiac hypertrophy, metabolic abnormalities, smoking habits, elevated angiotensin II levels, endothelial dysfunction, and inflammation. Microalbuminuria seems to reflect the influence of these parameters on the arterial wall, and therefore can be considered as an integrated marker of cardiovascular risk.

    Article  PubMed  CAS  Google Scholar 

  12. Martinez MA, Moreno A, Aguirre de Carcer A, et al., MAPA--Madrid Working Group: Frequency and determinants of microalbuminuria in mild hypertension: a primary-carebased study. J Hypertens 2001, 19:319–326.

    Article  PubMed  CAS  Google Scholar 

  13. Jones CA, Francis ME, Eberhardt MS, et al.: Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 2002, 39:445–459.

    PubMed  Google Scholar 

  14. Wachtell K, Olsen MH, Dahlof B, et al.: Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2002, 20:405–412. This paper shows that in patients with moderately severe hypertension, left ventricular hypertrophy on two consecutive electrocardiograms is associated with increased prevalence of micro- and macroalbuminuria compared with patients without persistent electrocardiogram left ventricular hypertrophy, an association which is independent of age, blood pressure, diabetes, race, serum creatinine, or smoking.

    Article  PubMed  CAS  Google Scholar 

  15. Palatini P, Graniero GR, Mormino P, et al.: Prevalence and clinical correlates of microalbuminuria in stage I hypertension. Results from the Hypertension and Ambulatory Recording Venetia Study (HARVEST Study). Am J Hypertens 1996, 9:334–341.

    Article  PubMed  CAS  Google Scholar 

  16. Cirillo M, Senigalliesi L, Laurenzi M, et al.: Microalbuminuria in nondiabetic adults. Arch Intern Med 1998, 158:1933–1939.

    Article  PubMed  CAS  Google Scholar 

  17. Pontremoli R, Nicolella C, Viazzi F, et al.: Microalbuminuria is an early marker of target organ damage in essential hypertension. Am J Hypertens 1998, 11:430–438.

    Article  PubMed  CAS  Google Scholar 

  18. de la Sierra A, Bragulat E, Sierra C, et al.: Microalbuminuria in essential hypertension: clinical and biochemical profile. Br J Biomed Sci 2000, 57:287–291.

    PubMed  Google Scholar 

  19. Halimi JM, Forhan A, Balkau B, et al., D.E.S.I.R. Study Group: Is microalbuminuria an integrated risk marker for cardiovascular disease and insulin resistance in both men and women? J Cardiovasc Risk 2001, 8:139–146.

    Article  PubMed  CAS  Google Scholar 

  20. Toft I, Bonaa KH, Eikrem J, et al.: Microalbuminuria in hypertension is not a determinant of insulin resistance. Kidney Int 2002, 61:1445–1452.

    Article  PubMed  Google Scholar 

  21. Mennen LI, Balkau B, Royer B, et al.: Microalbuminuria and markers of the atherosclerotic process: the DESIR study. Atherosclerosis 2001, 154:163–1619. This paper reports on the relationship between microalbuminuria and tissue-type plasminogen activator antigen and fibrinogen in the subjects participating in the DESIR study.

    Article  PubMed  CAS  Google Scholar 

  22. Garg JP, Bakris GL: Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002, 7:35–43.

    Article  PubMed  Google Scholar 

  23. Leoncini G, Sacchi G, Viazzi F, et al.: Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach. J Hypertens 2002, 20:1315–1321. These results emphasize the value of microalbuminuria in the stratification of cardiovascular risk in hypertension.

    Article  PubMed  CAS  Google Scholar 

  24. Diercks GF, van Boven AJ, Hillege HL, et al.: Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study. Eur Heart J 2000, 21:1922–1927.

    Article  PubMed  CAS  Google Scholar 

  25. Turaj W, Slowik A, Wyrwicz-Petkow U, et al.: The prognostic significance of microalbuminuria in non-diabetic acute stroke patients. Med Sci Monit 2001, 7:989–994.

    PubMed  CAS  Google Scholar 

  26. Berton G, Cordiano R, Mbaso S, et al.: Prognostic significance of hypertension and albuminuria for early mortality after acute myocardial infarction. J Hypertens 1998, 16:525–530. This study demonstrates the existence of an association between microalbuminuria and adverse outcome in hypertensive patients who suffered acute myocardial infarction.

    Article  PubMed  CAS  Google Scholar 

  27. Redon J, Baldo E, Lurbe E, et al.: Microalbuminuria, left ventricular mass and ambulatory blood pressure monitoring. Kidney Int 1996, 49:S81-S84.

    Google Scholar 

  28. Pontremoli R, Ravera M, Bezante GP, et al.: Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. J Hypertens 1999, 17:993–1000.

    Article  PubMed  CAS  Google Scholar 

  29. Leoncini G, Sacchi G, Ravera M, et al.: Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. J Hum Hypertens 2002, 16:399–404.

    Article  PubMed  CAS  Google Scholar 

  30. Wachtell K, Palmieri V, Olsen MH, et al.: Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002, 143:319–326.

    Article  PubMed  Google Scholar 

  31. Gerstein HC, Mann JF, Pogue J, et al.: Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care 2000, 23(Suppl 2):B35-B39. This article describes the characteristics of diabetic and nondiabetic participants in the HOPE study who are at high risk of developing cardiovascular disease and who have microalbuminuria, and identifies the key determinants of microalbuminuria in these two groups.

    PubMed  Google Scholar 

  32. Ebihara I, Nakamura T, Shimada N, et al.: Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis 2000, 32:669–671.

    Google Scholar 

  33. Pedrinelli R, Penno G, Dell’Omo G, et al.: Microalbuminuria and transcapillary albumin leakage in essential hypertension. Hypertension 1999, 34:491–495.

    PubMed  CAS  Google Scholar 

  34. Agewall S, Wikstrand J, Ljungman S, et al.: Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group. Am J Cardiol 1997, 80:164–169.

    Article  PubMed  CAS  Google Scholar 

  35. Bulpitt CJ, Beevers DG, Butler A, et al.: The survival of treated hypertensive patients and their causes of death: a report from the DHSS hypertensive care computing project (DHCCP). J Hypertens 1986, 4:93–99.

    Article  PubMed  CAS  Google Scholar 

  36. Bigazzi R, Bianchi S, Baldari D, et al.: Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998, 16:1325–1333.

    Article  PubMed  CAS  Google Scholar 

  37. Jager A, Kostense PJ, Ruhe HG, et al.: Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999, 19:617–624.

    PubMed  CAS  Google Scholar 

  38. Jensen JS, Feldt-Rasmussen B, Strandgard S, et al.: Arterial hypertension, microalbuminuria, and ischemic heart disease. Hypertension 2000, 35:898–903. These data, obtained in a population-based sample of 2085 subjects aged 30 to 60 years who were free from ischemic heart disease, diabetes mellitus, and renal or urinary tract disease, show that microalbuminuria confers a fourfold increased risk of ischemic heart disease among hypertensive subjects.

    PubMed  CAS  Google Scholar 

  39. Redon J, Rovira E, Miralles A, et al.: Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002, 39:794–798.

    Article  PubMed  CAS  Google Scholar 

  40. Redon J: Renal protection with antihypertensive drugs: insights from the microalbuminuria studies. J Hypertens 1998, 16:2091–2100.

    Article  PubMed  CAS  Google Scholar 

  41. Monster TB, Janssen WM, de Jong PE, et al., PREVEND Study Group: The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population. Br J Clin Pharmacol 2002, 53:31–36.

    Article  PubMed  CAS  Google Scholar 

  42. Erley CM, Haefele U, Heyne N, et al.: Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs. Hypertension 1993, 21:810–815.

    PubMed  CAS  Google Scholar 

  43. Agrawal B, Wolf K, Berger A, et al.: Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. J Hum Hypertens 1996, 10:551–555.

    PubMed  CAS  Google Scholar 

  44. Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000, 321:1440–1444.

    Article  CAS  Google Scholar 

  45. Berger ED, Bader BD, Ebert C, et al.: Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition. J Hypertens 2002, 20:739–743. This trial shows that dual blockade of the renin-angiotensin system with an angiotensin II antagonist and a low-dose angiotensin-converting enzyme inhibitor can be profitably used in patients with hypertension and microalbuminuria.

    Article  PubMed  Google Scholar 

  46. Parving HH, Hovind P: Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin IIreceptor blockers for treating early and preventing clinical nephropathy. Curr Hypertens Rep 2002, 4:387–393.

    PubMed  Google Scholar 

  47. Andersen NH, Mogensen CE: Angiotensin converting enzyme inhibitors and angiotensin ii receptor blockers: evidence for and against the combination in the treatment of hypertension and proteinuria. Curr Hypertens Rep 2002, 4:394–402.

    PubMed  Google Scholar 

  48. Remuzzi A, Perico N, Sangalli F, et al.: ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 1999, 276:F457-F466.

    PubMed  CAS  Google Scholar 

  49. Bakris GL: Microalbuminuria: what is it? Why is it important? What should be done about it? J Clin Hypertens 2001, 3:99–102.

    CAS  Google Scholar 

  50. Keane WF, Eknoyan G: Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999, 33:1004–1009.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Clinica e Sperimentale, Università di Padova, via Giustiniani, 2, 35128, Padova, Italy

    Paolo Palatini MD

Authors
  1. Paolo Palatini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Palatini, P. +Microalbuminuria in hypertension. Current Science Inc 5, 208–214 (2003). https://doi.org/10.1007/s11906-003-0022-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-003-0022-0

Keywords

Search

Navigation